Abstract | The upregulation of immune checkpoint molecules, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4), on immune cells occurs during acute infections, such as malaria, as well as during chronic persistent viral infections, including HIV and hepatitis B virus. These pathways are important for preventing immune-driven pathology but can also limit immune-mediated clearance of the infection. The recent success of immune checkpoint blockade in cancer therapy suggests that targeting these pathways would also be effective for preventing and treating a range of infectious diseases. Here, we review our current understanding of immune checkpoint pathways in the pathogenesis of infectious diseases and discuss the potential for therapeutically targeting these pathways in this setting.
Immune checkpoint molecules are inhibitory recep tors expressed on immune cells that trigger immuno suppressive signalling pathways. These molecules are crucial for maintaining selftolerance and for modu lating the length and magnitude of effector immune responses in peripheral tissues to minimize collateral tissue damage 1, 2 . Signalling through these molecules can drive effector immune cells (especially T cells) into a state known as 'exhaustion' . T cell exhaustion is defined by reduced effector function, sustained expression of immune checkpoint molecules (such as programmed cell death protein 1 (PD1)), poor recall responses and a transcriptional state distinct from that of functional effector or memory T cells 3 . There are numerous types of activating and inhibitory interactions that occur between antigenpresenting cells (APCs) and T cells, and these interactions regulate the nature of immune responses (FIG. 1) . It is now clear that many pathogens and cancers promote inhibitory interactions between immune cells through immune checkpoint proteins to escape immune control.
Investigation of these immunosuppressive inter actions has led to the clinical development and licensing of new cancer treatments, which increase immune responses by using specific antibodies to block immune checkpoint molecules
. Antibodies targeting PD1 (pembroli zumab, nivolumab), cytotoxic T lymphocyte antigen 4 (CTLA4) (ipilimumab) and programmed cell death 1 ligand 1 (PDL1, also known as B7H1) (atezolizumab, avel umab and durvalumab) are currently licensed as mono therapies for various types of cancer (BOX 2) . In addi tion, combined therapeutic targeting of PD1 and CTLA4 was shown to be more effective than either therapy alone for treatment of melanoma 4 , although such combina tion therapy also leads to increased toxicity in patients. Therapies targeting several other immune checkpoint pathways have also shown promise for controlling var ious types of cancer (TABLE 1; reviewed in REF. 2) . It is also possible to increase immunity by directly target ing costimulatory molecules on T cells with agonistic antibodies (BOX 1) , and the clinical utility of such treat ments is currently being assessed in clinical trials. These antibodymediated treatments use the individual's own immune system to eliminate or slow the growth of cancer cells and have shown remarkable success in malignancies such as melanoma.
A major challenge in immunotherapy is to under stand why treatment responses are variable, and thus there is a search for predictive 'biomarkers' of a favour able clinical response. PDL1 expression on tumour cells can identify patients who would most benefit from PD1 or PDL1 blockade therapy 5 . There are also more complex 'gene signatures' in tumours that can identify patients who will show the best responses to immuno therapies 6 . Earlier expansion of T cell populations fol lowing antiPD1 antibody therapy in smallcell lung cancer has been associated with improved responses 7 , and a composite biomarker of the T cell proliferative response together with pretreatment tumour burden can predict responses to antiPD1 antibody in individuals with metastatic melanoma 8 . Given the cost and toxicity of immune checkpoint blockade, identifying biomarkers that predict a clinical response is currently a top priority.
Whether immunotherapies can also be effective for treating infectious diseases is less well explored. However, the fact that these inhibitory pathways are also MHC exploited for immune evasion by pathogens suggests that their blockade could be used for the prevention and treat ment of infectious diseases, in either the acute or chronic phases of infection. Currently, checkpoint blockade is being evaluated for reversing T cell exhaustion that follows from chronic infectious disease, but there is potential for also treating acute infections to generate longterm immu nity 9 . The development of vaccines for a range of infec tious diseases, including malaria, hepatitis B virus (HBV) and HIV could also potentially be improved through immune checkpoint blockade. Given that drug resistance in malaria 10 and many other infections is increasing and that control of both HIV and HBV requires lifelong treat ment, new strategies for potentially curing these infections are being considered. Furthermore, parallel searches for biomarkers that will provide information on the best therapy choice as well as indicate if there is a time frame when immunotherapy would be most efficacious are also required. In this Review, we describe in detail the impact of immune checkpoint signalling during malaria, HIV and HBV infections, as well as in tuber culosis (TB), and we discuss the potential for therapeutically targeting these pathways in these settings.
Immune checkpoint proteins in malaria
Malaria is a mosquitoborne infectious disease of humans caused by parasitic protozoans of the genus Plasmodium. The majority of malaria infec tions are caused by Plasmodium falciparum and Plasmodium vivax, and in 2015, there were 212 million new cases of malaria worldwide, with 429,000 deaths due to P. falciparum alone 11 . These parasites have a complex , regulate antigen-specific T cell responses to pathogens or malignant cells. The T cell receptors (TCRs) on antigen-specific T cells first recognize their cognate antigens, which are presented on MHC molecules on APCs (signal 1). This step must be followed by a signal to CD28 on T cells from CD80 on the APCs, which is described as 'signal 2'. Several different ligands on DCs then provide signals to T cells that determine the quality and duration of the effector response. Receptor-ligand interactions that amplify effector T cell responses (indicated by green arrows) include CD40-CD40 ligand (CD40L), OX40-OX40L, 4-1BB−4-1BBL (also known as CD137L), inducible T cell co-stimulator (ICOS)-ICOSL and CD27-CD70. There are also receptor-ligand interactions that suppress effector T cell responses (red square arrows) to maintain self-tolerance and limit the duration of the immune responses to minimize bystander damage to host tissue. These include lymphocyte activation gene 3 protein (LAG3)-MHC class II, T cell immunoglobulin mucin receptor 3 (TIM3)-galectin 9, programmed cell death protein 1 (PD1)-programmed cell death 1 ligand 1 (PDL1), PD1-PDL2, T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT)-CD155, cytotoxic T lymphocyte antigen 4 (CTLA4)-CD86 or CTLA4-CD80, glucocorticoid-induced TNFR-related protein (GITR)-GITR ligand (GITRL) and B and T lymphocyte attenuator (BTLA)-herpes virus entry mediator (HVEM). The '?' refers to an unknown receptor that 'activates' T cells. 
Examples:
• Anti-OX40 antibody • Anti-4-1BB antibody life cycle within the mammalian host, in which a liver stage of infection is followed by asexual and sexual blood stages of infection. The blood stages cause the severe symptoms and high mortality associated with malaria.
Over the past 20 years, more than 100 vaccines have been developed to control malaria, and these have been clinically evaluated. Most vaccines were specifically designed to target liverstage or bloodstage parasites by inducing protective antibodies and CD4 + T cells, although a few vaccines were designed to generate CD8 + T cell responses against the liverstage parasites. The best candidate vaccine identified to date is the RTS,S/AS01E vaccine, which will soon be administered to children in Africa; however, this vaccine had an efficacy of only 43.6% in the first year of administration, and efficacy decreased to 16.8% by the fourth year 12 . This result high lights considerable challenges in developing an effective malaria vaccine and suggests that new strategies that target potential mechanisms of immune evasion by parasites need consideration.
The symptoms of malaria range from asymptomatic to chronic, severe and finally lethal disease. Partial immu nity is developed by those living in endemic areas only after repeated malarial infection over several years [13] [14] [15] . Protection against malaria is dependent on both cell mediated and humoral immune responses. Parasites in the liver stage are known to be cleared by cytotoxic CD8 + T cells and possibly CD4 + T cells 16 . For bloodstage malaria, antibodies have been shown to play a key role in protection, as demonstrated by the transfer of serum from protected adults into children 17 . Studies in experimental rodent models of malaria have shown that multiple effec tor responses are required to protect against bloodstage malaria. T helper 1 (T H 1) cell responses are critical for controlling the bulk of bloodstage parasites and thus pre venting severe disease 18, 19 . Antibodies are required to elim inate the remaining patent parasites 20 . Recent studies have shown that CD8 + T cells are required for sterile immu nity that prevents the acute infection from progressing to chronic malaria 21 . There are four mouse models of malaria that dis play the major symptoms and pathology of human disease and are routinely used to study malarial patho genesis
. A definitive role for PD1 in malar ial patho genesis was established when PD1deficient mice were shown to rapidly and completely clear Plasmodium chabaudi infections, which usually cause chronic malaria in mice 21 . Notably, during the acute phase of P. chabaudi infection, PD1 was shown to medi ate a 95% loss in the numbers and functional capacity of parasite specific CD8 + T cells, which are required to control chronic disease 21 . Recent studies of malaria using four mouse mod els revealed a novel regulatory function for PDL2 (also known as B7DC) 9 . It was shown that whereas PDL1 expressed by DCs did indeed attenuate immune responses against malaria, PDL2 protein expressed on the same DCs improved immune responses by inhibit ing PDL1-PD1 interactions 9 . These studies also showed that PDL2 was essential for establishing effective T H 1 cell immunity for protection against lethal malaria (FIG. 2) . This study also examined healthy human volunteers before and after infection with experimental P. falciparum malaria. The authors found that the expression of PDL2, but not PDL1, on blood DCs decreased significantly within 7 days of infection to levels that inversely corre lated with the level of parasitaemia in each individual 9 . In other words, higher PDL2 levels correlated with lower parasitaemia, indicating that this was not just a feature of mouse malaria. Overall, this study highlighted the importance of PDL2 expression for malarial immunity. During Plasmodium berghei infections in mice resist ant to cerebral malaria, antibodymediated blockade of either CTLA4 or PDL1, but not PDL2, resulted in higher levels of T cell activation with improved IFNγ produc tion but increased the incidence of cerebral malaria in these mice 31 . This was most likely because CTLA4 or PDL1 blockade did not improve CD4 + T cell func tions sufficiently to control systemic parasite growth and sequestration in the brain before improved CD8 + T cell functions could cause bystander pathology in the brain. By contrast, administering soluble multimeric PDL2-Fc fusion protein reduced the incidence of cere bral malaria by 78% 9 . Similarly, blocking TIM3 signal ling with an antibody restored lymphocyte activity in Plasmodium infections, resulting in accelerated parasite clearance and reduced symptoms of cerebral disease in P. bergheiinfected mice 29 . The suppressive function of T reg cells in lethal P. yoeliiinfected mice was inhibited by GITR blockade, indicating another potential target 32 . B and T lymphocyte attenuator (BTLA; also known as CD272) has also been associated with cerebral malaria, and blockade of this inhibitory molecule significantly reduced the incidence of cerebral malaria compared with control mice 33 . Overall, several checkpoint proteins contribute to the pathogenesis of malaria, and further investigation of their potential as therapeutic targets is warranted. These therapies may also have the potential to be used to 'reinvigorate' immune cells, which are suggested to be nonresponsive in areas where malaria is endemic 26, 27 , to allow vaccines to generate longterm immunity. Alternatively, checkpoint blockade could complement malarial drugs to generate longterm immunity, as seen for PDL2-Fc 9 .
Immune checkpoint proteins in HIV There are 37 million people living with HIV, and each year there are 2 million new infections and 1 million deaths 34 . Antiretroviral therapy (ART) has dramatically reduced HIVrelated morbidity and mortality, but only 40% of people living with HIV globally are receiving ART 34 , and there is no vaccine or cure. Lifelong ART is required, as once treatment is stopped, the virus rap idly rebounds. Given the social and economic impact of the lifelong medical care required for people living with
Box 2 | Overview of immune checkpoint molecules in cancer therapy
Below, we describe three checkpoint molecules that are currently targeted for cancer therapy and one being tested in clinical trials. Therapies targeting several other immune checkpoint pathways have also shown promise for controlling various cancers, and some of these drugs have progressed to clinical trials (TABLE 1; REF. 108 ).
CTLA4
Cytotoxic T lymphocyte antigen 4 (CTLA4) is a member of the immunoglobulin superfamily and is expressed by activated T cells together with the T cell co-stimulatory protein CD28. Both molecules bind to CD80 and CD86 on dendritic cells (DCs), but CTLA4 binds with greater affinity and avidity than CD28. Whereas CD28 transmits a stimulatory signal 109 , CTLA4 is able to outcompete CD28 for CD80 and CD86 binding to inhibit T cell functions 110 . Of note, CTLA4 expression on effector T cells is increased only after T cell receptor (TCR)-mediated and CD28-mediated T cell activation to permit downstream control of immunity.
PD1
Programmed cell death protein 1 (PD1) has potent inhibitory effects on immunity. PD1 is expressed on T cells, B cells, natural killer T cells, DCs and activated monocytes 111, 112 . PD1 has two ligands, programmed cell death 1 ligand 1 (PDL1) and PDL2. PD1 expression is upregulated on the surface of T cells within 24 hours of TCR stimulation, and the effects of PD1 ligation can be seen within a few hours 113 . Importantly, signalling in T cells through PD1 following engagement with PDL1 expressed on DCs and tumour cells attenuates TCR signalling and inhibits T cell population expansion, cytokine production and cytolytic function 114 . New studies demonstrate that the CD28-B7 co-stimulatory pathway is essential for effective PD1-targeted therapy in tumour-bearing mice and during chronic viral infection 115 .
PDL1

PDL1 drives PD1-mediated immune inhibition and is constitutively expressed on T cells, B cells, macrophages and DCs
116
, in non-lymphoid tissues such as the heart and lungs 111 , in parenchymal cells 117 , and on the surface of tumour cells 118 . Expression of PDL1, but not PDL2, is also detected at low levels on cardiac endothelium, pancreatic islets and syncytiotrophoblasts in the placenta, highlighting a role for PDL1 in immunological tolerance 119 . PDL1 blockade has also demonstrated efficacy in lung, bladder and other cancers [120] [121] [122] .
PDL2
PDL2 is also an immune checkpoint inhibitor, but its function is not as well understood as that of PDL1, and thus its clinical utility is still being explored. The engagement of PD1 by PDL2 dramatically inhibits TCR-mediated proliferation and cytokine production by CD4 + T cells 123 . Antigen-presenting cells (APCs) from PDL2-deficient mice demonstrated an increased potential to activate T cells, both in vitro and in vivo 124 , suggesting that PDL2 has an inhibitory role similar to PDL1. However, recent studies showed PDL2 expressed as an aggregated form on DCs could inhibit PDL1 and/or PD1 binding and increase CD3 and inducible T cell co-stimulator (ICOS) expression on T cells, possibly via a putative second receptor 9 . Previous studies also showed that PDL2 could improve T cell function via a PD1-independent mechanism [125] [126] [127] . Thus, PDL2 has a complex function, and PDL2 proteins are being investigated in clinical trials.
HIV, finding a cure has become a major global prior ity 35 . Immune checkpoint proteins have been extensively studied during HIV infection, initially in relation to nat ural history and T cell function, but more recently in relation to complications of HIV infection. In addition, using immune checkpoint blockade could potentially be exploited as a strategy to achieve a cure.
T cell exhaustion and immune checkpoint proteins in HIV infection. T cell exhaustion is a hallmark of many chronic viral infections, including HIV. In untreated HIV infection, there is upregulated expression of multiple immune checkpoint proteins, including PD1, CTLA4, TIM3 and LAG3, on both CD4 + and CD8 + T cells [36] [37] [38] . Following ART, expression of immune checkpoint proteins declines but remains elevated compared with controls not infected with HIV
38
. Whether ART is started early (within 6 months of infection) or late (within 2 years of infection), similar expression levels of immune checkpoint proteins persist 39 . In HIV infection, expression of immune check point proteins varies on different T cell subsets. Increased expression of PD1 is predominantly seen on central mem ory T cells 40 , whereas both PD1 and CTLA4 are expressed by T reg cells and LAG3 is expressed by effector memory T cells 41 (FIG. 3) . In addition, PD1 is often coexpressed with proteins that help to promote T cell activation, such as CD38 and MHC class II molecules 42 .
Increased levels of PD1 expression on total and HIVspecific CD8 + T cells in untreated HIV infec tion were first reported more than 10 years ago 36, 43, 44 . PD1 is also highly expressed by cytotoxic CD8 + T cells that migrate into lymphoid follicles; these follicular cytotoxic CD8 + T cells express high levels of CXC chemokine receptor 5 (CXCR5) and PD1 but low levels of other immune checkpoint proteins, such as TIM3 (REF. 45 ). There is an inverse association between the frequency of cytotoxic CD8 + T cells and HIVinfected cells in lymphoid follicles, and a sim ilar inverse relationship has been recently observed in untreated simian immunodeficiency virus (SIV) infection [45] [46] [47] (TABLE 2) . Other beneficial effects of antiPD1 antibody treatment in the setting of SIV infection have included reduced interferon signalling and improved gut perme ability 55 . In preliminary work assessing the adminis tration of antiPD1 (REF. 56) or antiPDL1 (avelumab) 57 antibodies to SIVinfected macaques on ART, there were no adverse effects, but in contrast to the results of studies in rhesus macaques not receiving ART, there was limited expansion of SIVspecific CD8 + T cells 56 . It is possible that an effective T cell response to antiPD1 antibody requires the presence of antigen and that because ART leads to a dramatic reduction in viral antigens, the func tional response to immune checkpoint blockade may be limited in this setting. Further work is needed to better understand the effects of immune checkpoint blockade on T cell function following ART.
In individuals infected with HIV and not receiving ART, the upregulation of CTLA4 expression on HIV specific CD4
+ T cells was also demonstrated more than a decade ago, and similarly to the upregulation of PD1 expression, this was associated with increased HIV disease progression 37 . When SIVinfected macaques, both on and off ART, were treated with ipilimumab (antiCTLA4 antibody), those that were not receiving ART showed a significant increase in rates of HIV rep lication, presumably as a result of an increased number of activated CD4 + T cells, which would be targets for SIV infection 58 . In another study of SIVinfected macaques on partially suppressive ART, ipilimumab led to a mod est increase in both HIVspecific CD4 + and CD8 + T cells and a significant reduction in cellassociated HIV RNA in lymph nodes 59 . These data therefore suggest that antiCTLA4 antibody has a substantial effect on HIV that persists on ART, through a different mechanism of action to antiPD1 antibody, leading to a reduction in HIV RNA in lymph node tissue. However, the mecha nism by which this is achieved or whether there is anti body activity in individuals infected with HIV and on fully suppressive ART remains unknown.
In individuals infected with HIV, LAG3 is also highly expressed on CD4 + and CD8 + T cells in lymph nodes and blood, and this expression is directly related to lev els of HIV RNA in plasma but inversely related to CD4 + T cell counts 41 . Expression of T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) is also increased on CD8 + T cells in untreated and treated HIV infection compared with controls without HIV 38 even following early initiation of ART 60 . HIVspecific CD8 + T cells were almost exclusively TIGIT + and co expressed PD1, CD160 and 2B4 (also known as CD244) Many studies have shown a significant correla tion between the frequency of PD1 + CD4 + T cells and PD1 + CD8 + T cells with different markers of HIV per sistence on ART in the blood 63, 65, 66 , lymph nodes 67 and gastrointestinal tract, which has almost three times the frequency of PD1 + CD4 + T cells compared with the lymph nodes or blood 68 . However, the most direct evi dence of a clear relationship between HIV persistence and PD1 expression comes from sorting CD4 + T cells from blood, where a 10fold enrichment of HIV in PD1 hi CD4 + T cells compared with PD1 low CD4 + T cells was observed 63 . Similar findings were also reported from
Box 3 | Mouse models of malaria
Mouse models of malaria have provided useful information regarding the extent to which checkpoint proteins inhibit natural immunity. Four of the species and strains of Plasmodium most commonly used to infect mice show distinct biology and pathogenicity. Plasmodium yoelii 17XNL and Plasmodium chabaudi blood-stage infections are non-lethal, with the latter causing chronic disease with intermittent parasitaemia for up to 200 days. By contrast, Plasmodium yoelii YM and Plasmodium berghei ANKA infections are severe, lethal infections, with the latter being sequestered from the blood into deep tissues including the brain, leading to lethal cerebral disease.
T cell exhaustion (lethal malaria)
Soluble PDL2 used as a therapy to prevent exhaustion
Naturally expressed PDL2 outcompetes PDL1 for PD1 to prevent exhaustion (non-lethal malaria)
lymph node tissue collected from individuals infected with HIV and on ART, where HIV was highly enriched in cells expressing PD1 and CXCR5, which together identify T FH cells 67 (FIG. 3) . HIV enrichment in PD1 hi cells may be due to the inhibitory effects of PD1 on T cell activation, which would limit HIV transcription, RNA export and RNA translation and therefore favour latent infection over productive infection (FIG. 4) .
Immune checkpoint proteins other than PD1 may also identify infected cells in individuals on ART. We recently demonstrated that HIV was significantly enriched in sorted cells obtained from individuals infected with HIV on ART that expressed PD1, TIGIT and LAG3 compared with cells that expressed none of these immune checkpoint proteins 64 (FIG. 3) . The relation ship between CTLA4 and virus persistence on ART has been less well studied. In untreated individuals, HIV replicates preferentially in activated CD4 + T cells, which express high levels of CTLA4, and therefore virus is enriched in CTLA4 + CD4 + T cells 69 . Rapid internalization of CTLA4, mediated by the viral protein Nef, may poten tially play a role in favouring HIV persistence in these cells 70 . Whether latently infected CTLA4 + CD4 + T cells in the blood or tissues persist on ART is currently unclear.
These exciting observations are now being exploited by using immune checkpoint blockers to potentially reverse latency, allowing for expression of HIV proteins on the surface of the cell, which would lead to immune clearance of the virus or virusinduced cytolysis (FIG. 4) . Latency reversal would be attempted in individuals on ART, so that any new virus produced could not go on to infect other cells. Through the use of CD4 + T cells from individuals with HIV infection on ART, the ex vivo administration of antiPD1 antibody together with the latencyreversing agent bryostatin led to a signif icant increase in HIV RNA released into the supernatant (N. Chomont, personal communication). In addition, in an individual infected with HIV on ART with meta static melanoma, we observed a significant increase in cell associated HIV RNA following treatment with antiCTLA4 (ipilimumab) 71 and antiPD1 (nivolumab) antibodies 72 . These results need to be confirmed in other HIVinfected individuals on ART who are now receiving checkpoint blockade for the management of cancer. The effects of other immune checkpoint blockers on latency establishment or reversal are unknown and warrant further exploration using antibodies, either alone or in combination.
Clinical trials of immune checkpoint blockade as a strategy for curing HIV.
A phase II doseescalation study of antiPDL1 antibody therapy (by BristolMyers Squibb) was recently ceased after administration of the lowest dose to six individuals with HIV infection on ART 73 . The study was stopped due to retinal toxicity observed in a simultaneous macaque study. Interestingly, although there were no changes in levels of HIV RNA or DNA, there was a clear increase in Gagspecific CD4 + and CD8 + T cells in two of the six participants. One of the six participants developed hypophysitis many months after receiving antiPDL1 antibody therapy. This study remains the only trial of an immune check point blocker in individuals with HIV infection without malignancy, and further trials are unlikely to proceed until more safety data for these compounds are available.
To date, few individuals with HIV infection have received even the currently licensed immune check point blockers, as individuals with HIV infection were excluded from the initial clinical trials of these agents. However, now that these drugs are licensed, many indi viduals with HIV infection are receiving these anti bodies as part of clinical care. Several clinical trials in the US and France are currently evaluating the effects of antiPD1 and antiCTLA4 antibodies either alone or in combination on HIVassociated malignancies, as well as on markers of HIV persistence and HIVspecific immunity (reviewed in REF. 74 ).
In summary, immune checkpoint blockers could have multiple beneficial contributions towards achieving a cure or allowing individuals to safely stop ART (FIG. 4) . First, the administration of these drugs could potentially increase HIVspecific T cell function to eliminate HIVinfected cells. Second, they may lead to direct elimination of infected cells that express the relevant immune checkpoint marker, particularly when using a depleting antibody that activates Fc receptors, as described for ipilimumab 75 and modified antibodies against PD1 (REF. 76 ). Third, immune checkpoint blockers could potentially reverse HIV latency. Finally, immune checkpoint blockers can increase vac cine responsiveness 77 and therefore could potentially be combined with other therapeutic vaccines in development.
Immune checkpoint proteins in HBV infection
HBV is a DNA virus that predominantly replicates in the hepatocytes of the liver. Following entry of HBV into a hepatocyte, there is production of intracellular covalently closed circular DNA (cccDNA), which pro duces multiple forms of HBV RNA and HBV proteins, including hepatitis B surface antigen (HBsAg), as well as HBV DNA, which is required to form new infectious virions. Globally, there are 250 million people living with chronic HBV 78 , and the main complications include endstage cirrhosis and/or hepatocellular carcinoma (HCC) 79 . HBV can be effectively treated with selflimited interferon therapy or, more commonly, with longterm antiviral treatment using nucleotide-nucleoside reverse transcriptase inhibitors (NRTIs). Similarly to ART in individuals with HIV infection, treatment with NRTIs is lifelong, and there is no cure for HBV 80 . However, in contrast to HIV, approximately 10-15% of individuals can safely stop NRTI treatment for HBV without viral rebound. Inducing antiviralfree remission for HBV is possible with the development of antibodies to HBsAg, commonly referred to as seroconversion 80 .
T cell exhaustion and immune checkpoint proteins in HBV infection. HBVspecific T cells are important in HBV pathogenesis, where they play a role in the initial clearance of acute infection, abnormal liver function commonly observed in acute and chronic infection, 82, 83 . In untreated chronic HBV infection, total and HBV specific CD8 + T cells express high levels of PD1, CTLA4 and TIM3 , and in acute HBV infection, circulating and intrahepatic CD8 + T cells express high levels of PD1 (REF. 87; FIG. 3) . The upregulation of PD1 expression in acute HBV infection is thought to limit intrahepatic inflammation 87 . The ligand for PD1, PDL1, has also been shown to be elevated on circulating CD14 + monocytes and CD19 + B cells in individuals with chronic HBV infection, liver cirrhosis and HCC and therefore may contribute to ongoing T cell exhaustion 88 . These exhausted antigenspecific CD8 + T cells are prone to apoptosis through coexpression of the proapoptotic protein BIM (also known as BCL2L11) 86 . By contrast, HBVspecific CD4 + T cells, defined by MHC class II tetramers and HBV core peptides, expressed increased levels of PD1, but no increase in CTLA4, TIM3, KLRG1 or 2B4 expression was observed 89 (summarized in FIG. 3) . A recent genomewide expressionprofiling study of HBVspecific CD8 + T cells from individuals with acute and chronic HBV infection revealed extensive down regulation of multiple pathways, including pathways associated with mitochondrial function, and T cells from these individuals showed functional recovery in the presence of mitochondrialtargeted antioxidants 90 . These studies demonstrated that defects in T cell function in chronic HBV infection are not limited to increased expression of immune checkpoint pro teins, although mitochondrial dysfunction was clearly enriched in PD1 hi CD8
+ T cells in this study 90 . The phenotype of intrahepatic CD4 + and CD8 + T cells has also been extensively characterized in HBV infection. Initial descriptions of intrahepatic T cells in chronic HBV infection showed a high infiltration 84 . These intrahepatic CD8 + T cells also express other proteins of exhaustion, including BTLA, and can produce IL10, which further inhibits effective T cell function 92 .
Immune checkpoint blockade as a strategy for curing HBV. Multiple ex vivo studies using blood collected from individuals with chronic HBV infection have demonstrated that inhibition of PD1, CTLA4, 2B4 and TIM3 leads to increased HBVspecific CD8 + T cell function 83, 84, 86, [93] [94] [95] [96] . By contrast, only blockade of PD1 and not blockade of the other inhibitory proteins par tially improved HBVspecific CD4 + T cell functions, with increased production of IFNγ, IL2 and tumour necrosis factor (TNF) 89 . Checkpoint blockade, used either alone or in combination, may potentially increase the production of HBVspecific CD8 + T cells and even the production of antibodies against HBsAg, but there are substantial theoretical risks, including increased infiltration of reinvigorated T cells into the liver, which could trigger inflammation, but this has not been demonstrated in preclinical studies or recent clinical trials.
The effects of PD1 blockade in vivo during HBV infection have been evaluated in mouse and wood chuck models. Blockade of the PD1-PDL1 or PD1-PDL2 pathways with antiPDL1 and antiPDL2 antibodies in woodchuck hepatitis virus (WHV) infected animals partially restored T cell function with out hepato toxicity 97 . In a separate study of WHV, the combination of antivirals (entecavir), therapeutic vac cination and antiPDL1 antibody blockade, followed by cessation of entecavir, did not result in rebound of WHV in plasma and instead led to the development of anti bodies against WHV surface antigens, with com plete viral clearance in some animals 98 . Interestingly, the addition of antiPDL1 antibody to the vaccine and entecavir arm compared with the vaccine and ente cavir alone arm led to a significantly increased immuno logical and clinical response and was not associated with hepatotoxicity 98 . These studies look very prom ising for similar interventions to achieve sustained remission off NRTIs in human clinical trials.
A recent openlabel study of nivolumab (antiPD1 antibody; 0.3 mg per kg) with and without an HBV vac cine involving 20 participants with virally suppressed chronic HBV infection showed that nivolumab was safe and well tolerated, and one participant underwent HBsAg seroconversion 99 . Many other clinical trials of immune checkpoint blockade in individuals with chronic HBV, usually in the setting of HCC, are currently underway. One major study is a phase 1/2, openlabel, noncomparative, dose escalation and expansion trial (CheckMate 040) of nivolumab in adults (≥18 years) with histologically confirmed advanced HCC with or without HCV or HBV infection 100 . Symptomatic treatmentre lated adverse events were similar in patients with and without HCV or HBV infection 100 , which is encouraging and the trial recently led to the licensing of nivolumab for HCC. Future cohorts within CheckMate040 which includes individuals with HBV on antiviral therapy will also examine nivolumab with other agents, includ ing antiCTLA4 (NCT01658878). Another 60month observational study, led by the Taiwan Food and Drug Administration, is also in progress (NCT02402699). This is a study of individuals in Taiwan with known HBV or HCV infection, regardless of control on antiviral therapy, and who are being treated with ipilimumab for advanced (unresectable, recurrent or metastatic) melanoma. Many other studies of immune checkpoint blockade for HCC that do not specifically exclude individuals with chronic HBV are currently enrolling participants.
In summary, immune checkpoint proteins play an important role in the natural history of HBV infection, limiting liver damage in acute infection and potentially facilitating persistent infection in chronic HBV infec tion. Initial studies indicate that nivolumab is safe in chronic HBV infection, but further studies are needed to determine whether antiPD1 antibody and/or other immune checkpoint blockers can be used to induce HBV remission. + T cells from indi viduals with active infection were only slightly higher those on than cells from healthy donors 102 . Notably, HIV and TB coinfection was consistently and inde pendently associated with a reduced frequency of mycobacterialspecific CD4 + T cells secreting both IFNγ and IL2, and the proportion correlated inversely with HIV RNA levels in plasma 101 . Mouse models used to determine the contribu tion of PD1 to TB pathogenesis have yielded conflict ing results. Surprisingly, mice with a deletion of Pdcd1, which encodes PD1, showed increased pathology, and PD1deficient CD4 + T cells are sufficient to trigger early mortality 103, 104 . The lungs of the PD1deficient mice showed uncontrolled bacterial proliferation and focal necrotic areas with predominantly neutro philic infiltrates, but a lower number of infiltrating T and B cells 105 . Proinflammatory cytokines such as TNF and IL6 were significantly increased in the lungs and sera of these mice, consistent with aberrant inflammation 105 . Notably, TBspecific T cell proliferation was dramatically reduced in PD1deficient mice compared with controls due to an increased number of T reg cells and recruitment of mesen chymal stem cells 104 . Similarly, functionally exhausted TIM3 + T cells were shown to accumulate dur ing chronic TB infection, and TIM3 blockade restored T cell functions and improved control of the bacterial load in chronically infected susceptible mice 106 . The treatment of multidrugresistant TB (that is, in which the bacteria shows resistance in vitro to at least isoniazid and rifampicin) is complicated. To obtain a clinical and a microbiological cure, individuals are treated for long periods because of the lower effective ness of the secondline and thirdline drugs 107 . Long term exposure to these drugs, characterized by a poor safety and tolerability profile, reduces the adherence by individuals. The combination of these drugs with checkpoint inhibition may allow immunity to develop when the bacterial burden is under even partial con trol. For these reasons, checkpoint blockade during chronic TB infection requires further consideration.
Conclusion
Studies of the interplay between immune activation and suppression have shown an important role for immune checkpoint proteins in the pathogenesis of infectious diseases and malignancies. Notably, immune checkpoint blockade has revolutionized the treatment of cancer with remarkable success. A number of studies have suggested that immune checkpoint blockade may also be highly relevant for treating several infectious diseases, including malaria, HIV infection, HBV infection and TB (TABLE 2) ; in these diseases where drug resistance remains a challenge,
Box 4 | Adverse reactions and limited durability associated with immune checkpoint blockade
Blocking of checkpoint protein interactions with antibodies has shown to remarkably increase antitumour immunity; however, this immunity can be accompanied by immune-related adverse events resembling autoimmune diseases 128 . Immune-related adverse events can occur in up to 90% of patients treated with an anti-cytotoxic T lymphocyte antigen 4 (CTLA4) antibody 129 and 70% of patients treated with anti-programmed cell death protein 1 (PD1) and/or anti-programmed cell death 1 ligand 1 (PDL1) antibodies 130, 131 . These immune-related adverse events typically originate in the skin, gastrointestinal tract, liver and endocrine system, although other organ systems may also be affected 132 . While treatment with immunosuppressive drugs such as prednisolone is effective and usually resolves the symptoms, these adverse effects can be fatal. Therefore, substantial concerns remain around using these antibodies in otherwise healthy individuals living with HIV or hepatitis B virus (HBV). Autoimmune toxicities such as colitis, myocarditis and pneumonitis occur more commonly with anti-CTLA4 than anti-PD1 antibody treatment, and whether these can be reduced through modifications of the antibodies and/or reduction in dosage needs to be considered when exploring their use for infectious diseases.
Other factors that could reduce the efficacy of immunotherapies include non-responsiveness to treatment and limited durability of restored T cell functions. Blockade of the PD1-PDL1 pathway has shown durable benefit in melanoma and other cancers 130, 131, 133 , but >50% of patients do not respond or develop resistance to anti-PD1 antibody therapy. PD1 also plays a role in the setting of both acute and chronic infections. Whereas PD1 transcription is rapidly downregulated in functional antigen-specific CD8 + T cells that develop during acute infection, persistent TCR ligation during chronic viral infections maintains increased levels of PD1 transcription and the generation of a distinct lineage of non-functional 'exhausted' antigen-specific CD8 + T cells 134, 135 . These changes in T cell functions are persistent as a result of epigenetic modification, specifically demethylation of the promoter of PDCD1, which encodes PD1. These epigenetic changes persist even with reduction in antigen, as seen following effective antiviral therapy for HIV infection or following anti-PD1 antibody therapy [136] [137] [138] [139] . Thus, for infectious diseases, immunotherapy may have optimal effects when used with a vaccine to minimize immune suppression and thus permit vaccine responses to develop. Alternatively, immunotherapy used in conjunction with antimicrobial agents could allow long-term immunity to develop once the acute symptomatic infection has been controlled.
effective vaccine development has not been possible, or lifelong drug treatment is necessary. It should be recog nized, however, that immune checkpoint blockade may also cause immunerelated adverse events, as CTLA4, PD1, LAG3 and TIM3 are also involved in the regulation of peripheral tolerance to prevent autoimmunity
Furthermore, whether there will be variable responses to immune checkpoint blockade and clinical outcomes for infectious diseases also remains to be determined. Despite this, immune checkpoint blockade may be an important new strategy for tackling chronic infections for which we are still lacking effective therapies or vaccines.
